Your browser doesn't support javascript.
loading
A 6-bromoindirubin-3'-oxime incorporated chitosan-based hydrogel scaffold for potential osteogenic differentiation: Investigation of material properties in vitro.
Agnes, Celine J; Murshed, Monzur; Takada, Adrien; Willie, Bettina M; Tabrizian, Maryam.
Afiliação
  • Agnes CJ; Department of Biomedical Engineering, McGill University, Montreal, QC, Canada. Electronic address: celine.agnes@mail.mcgill.ca.
  • Murshed M; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada; Shriners Hospital for Children, Montreal, QC, Canada. Electronic address: monzur.murshed@mcgill.ca.
  • Takada A; Institute of Parasitology, McGill University, Montreal, QC, Canada. Electronic address: adrien.takada@mail.mcgill.ca.
  • Willie BM; Department of Biomedical Engineering, McGill University, Montreal, QC, Canada; Shriners Hospital for Children, Montreal, QC, Canada; Department of Pediatric Surgery, McGill University, Montreal, QC, Canada. Electronic address: bwillie@shriners.mcgill.ca.
  • Tabrizian M; Department of Biomedical Engineering, McGill University, Montreal, QC, Canada; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada. Electronic address: maryam.tabrizian@mcgill.ca.
Int J Biol Macromol ; 227: 71-82, 2023 Feb 01.
Article em En | MEDLINE | ID: mdl-36535349
ABSTRACT
Effective treatments for critical size bone defects remain challenging. 6-Bromoindirubin-3'-Oxime (BIO), a glycogen synthase kinase 3ß inhibitor, is a promising alternative for treatment of these defects since it aids in promoting osteogenic differentiation. In this study, BIO is incorporated into a new formulation of the guanosine diphosphate cross-linked chitosan scaffold to promote osteogenic differentiation. BIO incorporation was confirmed with 13C NMR through a novel concentration dependent peak around 41 ppm. The rapid gelation rate was maintained along with the internal structure's stability. The 10 µM BIO dose supported the control scaffold's microstructure demonstrating a suitable porosity and a low closed pore percentage. While pore sizes of BIO incorporated scaffolds were slightly smaller, pore heterogeneity was maintained. A proof-of-concept study with C2C12 cells suggested a dose-dependent response of BIO on early stages of osteogenic differentiation within the scaffold. These results support future work to examine BIO's role on osteogenic differentiation and biomineralization of encapsulated cells in the scaffold for bone regeneration.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteogênese / Quitosana Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteogênese / Quitosana Idioma: En Ano de publicação: 2023 Tipo de documento: Article